High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients

被引:38
|
作者
Leviev, I
Poirier, O
Nicaud, V
Evans, A
Kee, F
Arveiler, D
Morrisson, C
Cambien, F
James, RW
机构
[1] Univ Hosp Geneva, Clin Diabetes Unit, Div Endocrinol & Diabet, CH-1211 Geneva 14, Switzerland
[2] INSERM, Unite 525, Paris, France
[3] MONICA Project, Belfast, Antrim, North Ireland
[4] MONICA Project, Strasbourg, France
[5] MONICA Project, Glasgow, Lanark, Scotland
关键词
oxidative stress; vascular disease; gene polymorphisms; LDL; HDL;
D O I
10.1016/S0021-9150(01)00668-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Human paraoxonase-1 is hypothesised to protect serum lipoproteins from oxidative stress. Decreased serum activity of paraoxonase-1 in animal models is associated with an increased risk of vascular disease and has been linked to the anti-oxidant capacity of the enzyme. Promoter polymorphisms of the human paraoxonase-1 gene strongly influence serum concentrations of the enzyme. The present study examined the hypothesis that promoter polymorphisms may be genetic risk factors for vascular disease in man. Genotypes arising from the promoter (C-907)G polymorphism were analysed in the ECTIM2 population. The global odds ratio for myocardial infarction, comparing the high expressor GG genotype to other genotypes, was 0.77 (0.61-0.97) (P = 0.024). The association with the promoter genotype was more pronounced in the youngest age group (odds ratio 0.52 (0.31-0.87), P = 0.012) and was progressively lost with age (respectively 50 years to < 60 years, P 0.26; > 60 years, P = 0.45). There was no association between the promoter genotypes and serum lipids. The data are consistent with the high expressor promoter genotype being linked to reduced risk of myocardial infarction. The influence of the genotype may be compromised in older patients. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:463 / 467
页数:5
相关论文
共 50 条
  • [1] Genetic polymorphisms in the paraoxonase 1 (PON1) gene and the risk of coronary heart disease.
    Sanghera, DK
    Saha, N
    Kamboh, MI
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A210 - A210
  • [2] Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease
    Mackness, Bharti
    Turkie, Wajdi
    Mackness, Mike
    ARCHIVES OF MEDICAL SCIENCE, 2013, 9 (01) : 8 - 13
  • [3] Polymorphisms in the human paraoxonase (PON1) promoter
    Brophy, VH
    Hastings, MD
    Clendenning, JB
    Richter, RJ
    Jarvik, GP
    Furlong, CE
    PHARMACOGENETICS, 2001, 11 (01): : 77 - 84
  • [4] POLYMORPHISMS OF PON1 GENE ARE ASSOCIATED WITH CORONARY ARTERY DISEASE
    Liu, T.
    Zhang, X.
    Zhang, Y.
    Liang, Z.
    Cai, W.
    Sun, Y.
    Yan, C.
    Han, Y.
    HEART, 2015, 101 : A15 - A15
  • [5] Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
    Leviev, I
    James, RW
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) : 516 - 521
  • [6] DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease
    Sanghera, DK
    Aston, CE
    Saha, N
    Kamboh, MI
    AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (01) : 36 - 44
  • [7] The paraoxonase 1 (PON1) gene polymorphisms in coronary artery disease in the southeastern Turkish population
    Hazar, Abdussemet
    Dilmec, Fuat
    Goz, Mustafa
    Kocarslan, Aydemir
    Aydin, Mehmet Salih
    Demirkol, Abbas Heval
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2011, 41 (05) : 895 - 902
  • [8] Paraoxonase 1 (PON1) polymorphisms and risk for migraine
    Elena García-Martín
    Carmen Martínez
    Mercedes Serrador
    Hortensia Alonso-Navarro
    Francisco Navacerrada
    José A. G. Agúndez
    Félix Javier Jiménez-Jiménez
    Journal of Neurology, 2010, 257 : 1482 - 1485
  • [9] Paraoxonase (PON1) enzyme activity predicts vascular disease independently of PON1 promoter region or coding polymorphisms and of smoking and antihyperlipidemic use
    Jarvik, GP
    Heagerty, P
    Hatsukami, T
    Furlong, CE
    CIRCULATION, 2002, 105 (14) : E91 - E91
  • [10] Paraoxonase 1 (PON1) polymorphisms and risk for migraine
    Garcia-Martin, Elena
    Martinez, Carmen
    Serrador, Mercedes
    Alonso-Navarro, Hortensia
    Navacerrada, Francisco
    Agundez, Jose A. G.
    Javier Jimenez-Jimenez, Felix
    JOURNAL OF NEUROLOGY, 2010, 257 (09) : 1482 - 1485